Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

BELLUS Health Inc. (T:BLU)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEDAR
Company Contact
Address: 275 Armand-Frappier Blvd
Tel: 1-450-6804525
IR: See website
Key People
Francesco Bellini
Chairman of the Board
Roberto Bellini
President, Chief Executive Officer, Director
Denis Garceau
Senior Vice President- Drug Development
Francois Desjardins
Vice President - Finance
Tony Matzouranis
Vice President - Business Development
Sebastien Roy
Corporate Secretary
Business Overview
BELLUS Health Inc is a Canada-based biopharmaceutical development company. The Company's pipeline of projects includes the BLU-5937 for chronic cough and several other partnered clinical-stage drug development programs. BLU-5937 is a potent, selective, orally bio-available small molecule antagonist of the P2X3 receptor, a clinically validated target for chronic cough. BLU-5937 has the potential to help a number of chronic cough patients who do not respond to current therapies. BELLUS Health Inc also has economic interests in other partnered clinical-stage drug development programs, including KIACTA for sarcoidosis, AMO-01 for Fragile X Syndrome and ALZ-801 for APOE4 homozygous Alzheimer's disease.
Financial Overview
For the three months ended 31 March 2020, BELLUS Health Inc revenues decreased 43% to C$4K. Net loss increased from C$3.6M to C$10.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase from C$2.5M to C$6.6M (expense), General/Administration increase from C$1.1M to C$2.8M (expense).
Employees: 17 as of Dec 31, 2019
Reporting Currency: Canadian Dollars
Enterprise value: $183.79M as of Mar 31, 2020
Annual revenue (TTM): $0.03M as of Mar 31, 2020
EBITDA (TTM): -$38.58M as of Mar 31, 2020
Net annual income (TTM): -$39.81M as of Mar 31, 2020
Free cash flow (TTM): -$35.66M as of Mar 31, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 60,392,993 as of Jun 9, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization